Comparison · NCT00003838-e40deeaa
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality vs Group B: Stem Cell Transplant in Debilitating Hematologic Diseases: Number of Participants Overall Survival
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality vs Group B: Stem Cell Transplant in Debilitating Hematologic Diseases: Number of Participants Overall Survival. Trial comparisons, record NCT00003838-e40deeaa. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00003838-e40deeaa
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.395 | 0.264 | 0.544 | wilson | |
| Risk in group 2 | 0.842 | 0.726 | 0.915 | wilson | |
| Risk difference, group 1 minus group 2 | -0.447 | -0.597 | -0.258 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.469 | 0.319 | 0.691 | log | |
| Odds ratio, group 1 over group 2 | 0.123 | 0.048 | 0.313 | log | |
Number needed to treat, for one fewer participant with the outcome on Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality than on Group B: Stem Cell Transplant in Debilitating Hematologic Diseases | 2.24 | 1.67 | 3.87 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality | Participants at high risk for transplant related complications and mortality will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m\^2 intravenously daily x 5 days followed by a peripheral blood hematopoietic progenitor cell graft targeted to deliver \>5x10\^6 CD34+ cells/kg. | 17 | 43 | OG000 |
| Group 2 | Group B: Stem Cell Transplant in Debilitating Hematologic Diseases | Participants with hematologic diseases associated with reasonable longevity, shown to be curable by allogeneic Bone Marrow Transplant (BMT) but where concern for a high procedural mortality with conventional BMT will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m\^2 intravenously daily x 5 days followed by a peripheral blood hematopoietic progenitor cell graft targeted to deliver \>5x10\^6 CD34+ cells/kg. | 48 | 57 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Overall Survival
- Description
- Number of participants overall survival. Overall survival is defined as number participants alive following stem cell transplant
- Time frame
- enrollment to date of death, up to 5 years
- Population
- The analyses included only those participants that had a stem cell transplant
Source ClinicalTrials.gov
Trial
- Title
- Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
- NCT number
- NCT00003838
- Phases
- PHASE2
- Conditions
- Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
- Interventions
- T-cell replete PBPC allograft, Methotrexate, Cyclosporine, G-CSF
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Results first posted
- 2022-10-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00003838?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00003838-e40deeaa